SCHEDULE: PAVmed Inc. Insider Ownership Filing
Beneficial Ownership Filing
Lishan Aklog, Chairman and CEO of PAVmed Inc., reports beneficial ownership of 5.1% of the company's common stock.
Summary
- Lishan Aklog, M.D., Chairman and Chief Executive Officer of PAVmed Inc., has filed a Schedule 13D detailing his beneficial ownership of the company's common stock.
- As of April 2, 2026, Dr. Aklog beneficially owns 369,068 shares, representing 5.1% of the outstanding common stock.
- This ownership includes shares held directly, shares held by associated entities (HCFP/AG LLC, Pavilion Venture Partners LLC), shares held by his children, and shares issuable upon option exercise.
- The filing indicates that Dr. Aklog acquired 350,000 shares of restricted common stock on April 2, 2026, as consideration for services rendered.
- Dr. Aklog has no current plans for extraordinary corporate transactions, asset sales, or changes to the board or management, other than those consistent with his CEO role.
- The filing also details various option agreements and restricted stock agreements with the Issuer, outlining exercise prices, expiration dates, and vesting schedules.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this filing as neutral, primarily reporting on existing ownership and standard executive compensation arrangements without significant new strategic information or performance indicators.
Positives
- Dr. Aklog's significant beneficial ownership (5.1%) indicates strong alignment between key management and shareholder interests.
- The acquisition of 350,000 restricted shares on April 2, 2026, demonstrates continued investment in the company by its CEO.
- The filing confirms Dr. Aklog's commitment to his role as Chairman and CEO, with no immediate plans for actions that would disrupt the company's structure or operations.
Risks
- The restricted stock agreements and option agreements have specific vesting schedules and expiration dates, which could impact future share availability or executive compensation realization.
- The potential for Dr. Aklog to acquire additional securities or dispose of existing ones in the open market or private transactions could influence stock price dynamics.
- The filing notes that the company has no obligation to register the restricted shares for sale under the Securities Act of 1933, meaning resale could be subject to exemptions and limitations.
Future Outlook
Dr. Aklog may from time to time acquire additional securities or dispose of securities in the open market or private transactions. He has no current plans or proposals that would result in significant corporate changes such as mergers, asset sales, or changes to management or capitalization, beyond his role as CEO.
Management Comments
- Dr. Aklog acquired beneficial ownership of the shares for investment purposes.
- Dr. Aklog has no plans or proposals which would result in an extraordinary corporate transaction, a sale or transfer of a material amount of assets, or any change in the present board of directors or management of the Issuer.
Industry Context
StockSavvy.ai notes that this Schedule 13D filing by a key executive like the CEO of PAVmed Inc. is standard practice for reporting significant ownership stakes and potential future transactions. It provides transparency to investors regarding insider holdings and intentions, which is crucial in the biotechnology and medical technology sectors where PAVmed operates.
Stakeholder Impact
- Shareholders: Increased transparency regarding insider ownership and potential future stock transactions by the CEO.
- Employees: The CEO's continued investment and role may signal stability and commitment, potentially impacting employee morale.
- Creditors: No direct impact indicated, as the filing focuses on equity ownership and not debt.
Next Steps
- Dr. Aklog may continue to acquire or dispose of PAVmed Inc. securities.
- Vesting of restricted stock and exercise of stock options will occur according to their respective schedules.
Key Dates
| Date | Description |
|---|---|
| 04/02/2026 | Date of event requiring filing of Schedule 13D; Grant date of 350,000 restricted shares to Dr. Aklog. |
| 04/09/2026 | Date of certification of the Schedule 13D filing. |
| 04/28/2026 | Expiration date of an option agreement for 618 shares. |
| 05/20/2026 | Vesting date for restricted stock granted on May 1, 2020, and April 1, 2021. |
| 02/14/2028 | Expiration date of an option agreement for 433 shares. |
| 05/20/2028 | Vesting date for restricted stock granted on September 30, 2025. |
| 02/18/2032 | Expiration date of an option agreement for 444 shares. |
| 05/20/2029 | Vesting date for restricted stock granted on April 2, 2026. |
Keywords
PAVmed Inc., Schedule 13D, Lishan Aklog, Beneficial Ownership, Common Stock, Insider Trading, Restricted Stock, Stock Options, SEC Filing, Corporate Governance
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.